Demographics for total current cohort including patients with CCUS from the National MDS Study
| Demographic characteristic . | All patients (N = 37) . | Patients with CCUS (n = 23) . |
|---|---|---|
| Female, n (%) | 16 (43.2) | 9 (38.8) |
| Male, n (%) | 21 (56.8) | 14 (61.2) |
| Age, median [IQR] (min-max), y | 73.7 [70.6-79.7] (57.2-88.8) | 74.5 [70.85-80.95] (57.2-88.8) |
| Hemoglobin, median [IQR] (min-max), g/dL | 11 [10.1-12.3] (7.5-15) | 11.8 [10.8-12.6] (7.5-15) |
| WBC ×109/L | 4 000 [2 725-5 575] (1 700-13 570) | 4 000 [2 950-5 200] (1 700-10 100) |
| Plts ×109/L | 115 000 [80 500-188 500] (13 000-428 000) | 114 000 [73 500-181 500] (17 000-327 000) |
| VAF %, median [IQR] (min-max) | 25.3 [10.3-41.4] (2.2-97.9) | 21.7 [7.3-42.1] (2.2-97.9) |
| Median alternate allele read depth [IQR] (min-max) | 509 [186-892] (40-2 608) | 549 [151-916] (49-1 760) |
| MDS, n (%) | 11 (29.7) | n/a |
| MDS with excess blasts-2 (MDS-EB2; 10%-19% blasts), n (%) | 2 (18.2) | n/a |
| MDS with excess blasts-1 (MDS-EB1; 5%-9% blasts), n (%) | 3 (27.3) | n/a |
| MDS with multilineage dysplasia and ring sideroblasts (MDS-RSMLD), n (%) | 1 (9.1) | n/a |
| MDS with single lineage dysplasia and ring sideroblasts (MDS-RSSLD), n (%) | 2 (18.2) | n/a |
| MDS with multilineage dysplasia (MDS-MLD), n (%) | 2 (18.2) | n/a |
| MDS with isolated del(5q), n (%) | 1 (9.1) | n/a |
| MDS, unclassifiable (MDS-U), n (%) | 0 (0) | n/a |
| MDS with single lineage dysplasia (MDS-SLD), n (%) | 0 (0) | n/a |
| Number of Patients with MDS and variants, n (%) | 11 (100) | n/a |
| MDS # variants median [IQR] (min-max) | 4 [3-4] (1-5) | n/a |
| MDS VAF % median [IQR] (min-max) | 24.5 [10.9-36.3] (2.7-48.5) | n/a |
| MDS IPSS-R median [IQR] (min-max) | 2 [2-3.8] (1-4) | n/a |
| AML (<30% blasts), n (%) | 1 (2.7) | n/a |
| CCUS, n (%) | 23 (62.2) | n/a |
| MDS/MPN overlap, n (%) | 2 (5.4) | n/a |
| Demographic characteristic . | All patients (N = 37) . | Patients with CCUS (n = 23) . |
|---|---|---|
| Female, n (%) | 16 (43.2) | 9 (38.8) |
| Male, n (%) | 21 (56.8) | 14 (61.2) |
| Age, median [IQR] (min-max), y | 73.7 [70.6-79.7] (57.2-88.8) | 74.5 [70.85-80.95] (57.2-88.8) |
| Hemoglobin, median [IQR] (min-max), g/dL | 11 [10.1-12.3] (7.5-15) | 11.8 [10.8-12.6] (7.5-15) |
| WBC ×109/L | 4 000 [2 725-5 575] (1 700-13 570) | 4 000 [2 950-5 200] (1 700-10 100) |
| Plts ×109/L | 115 000 [80 500-188 500] (13 000-428 000) | 114 000 [73 500-181 500] (17 000-327 000) |
| VAF %, median [IQR] (min-max) | 25.3 [10.3-41.4] (2.2-97.9) | 21.7 [7.3-42.1] (2.2-97.9) |
| Median alternate allele read depth [IQR] (min-max) | 509 [186-892] (40-2 608) | 549 [151-916] (49-1 760) |
| MDS, n (%) | 11 (29.7) | n/a |
| MDS with excess blasts-2 (MDS-EB2; 10%-19% blasts), n (%) | 2 (18.2) | n/a |
| MDS with excess blasts-1 (MDS-EB1; 5%-9% blasts), n (%) | 3 (27.3) | n/a |
| MDS with multilineage dysplasia and ring sideroblasts (MDS-RSMLD), n (%) | 1 (9.1) | n/a |
| MDS with single lineage dysplasia and ring sideroblasts (MDS-RSSLD), n (%) | 2 (18.2) | n/a |
| MDS with multilineage dysplasia (MDS-MLD), n (%) | 2 (18.2) | n/a |
| MDS with isolated del(5q), n (%) | 1 (9.1) | n/a |
| MDS, unclassifiable (MDS-U), n (%) | 0 (0) | n/a |
| MDS with single lineage dysplasia (MDS-SLD), n (%) | 0 (0) | n/a |
| Number of Patients with MDS and variants, n (%) | 11 (100) | n/a |
| MDS # variants median [IQR] (min-max) | 4 [3-4] (1-5) | n/a |
| MDS VAF % median [IQR] (min-max) | 24.5 [10.9-36.3] (2.7-48.5) | n/a |
| MDS IPSS-R median [IQR] (min-max) | 2 [2-3.8] (1-4) | n/a |
| AML (<30% blasts), n (%) | 1 (2.7) | n/a |
| CCUS, n (%) | 23 (62.2) | n/a |
| MDS/MPN overlap, n (%) | 2 (5.4) | n/a |
IPSS-R, International Prognostic Scoring System; IQR, interquartile range; max, maximum; min, minimum; MPN, myeloproliferative neoplasms; n/a, not applicable.